CD274 and non-small cell lung carcinoma: Currently, anti-PD-1 antibodies, along with anti-PD-L1 antibodies, have become a cornerstone in the first-line treatment of advanced non-small cell lung cancer (NSCLC) without targetable oncogenic driver alterations [42].